MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

FDA Approves Merck's KEYTRUDA® (Pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy as a First-Line Treatment for Adults with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

NextEdge Admin

19 Sep 2024

2 min 28 sec

Merck , known as MSD outside the U.S. and Canada, has announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This approval follows positive data from the Phase 2/3 IND.227/KEYNOTE-483 trial.

The trial showed that the combination therapy significantly improved overall survival (OS), reducing the risk of death by 21% compared to chemotherapy alone (HR=0.79; p=0.0162). Median OS was 17.3 months for patients receiving KEYTRUDA plus chemotherapy versus 16.1 months for chemotherapy alone. Progression-free survival (PFS) also improved (HR=0.80; p=0.0194), with a median PFS of 7.1 months in both treatment groups. The overall response rate (ORR) was notably higher at 52% for the combination therapy compared to 29% for chemotherapy alone.

The study enrolled 440 patients with advanced or metastatic MPM, regardless of PD-L1 expression, and included patients without prior systemic therapy. Adverse reactions were generally consistent with those previously observed for KEYTRUDA in combination with chemotherapy, including immune-mediated adverse effects. Early identification and management of these reactions are critical for safe treatment.

Dr. Gregory Lubiniecki, vice president of oncology clinical research at Merck, emphasized the significance of this approval for MPM patients, a population with historically poor prognoses. This milestone highlights Merck’s dedication to advancing treatments for challenging cancers.

The trial was conducted in collaboration with international research groups, and Merck provided KEYTRUDA and support for the study.